In addition to our internal rare disease pipeline, we have established collaborations with biopharmaceutical companies who are leveraging the TransCon technology platform to develop products outside of rare endocrine diseases. Ascendis Pharma currently has two strategic product development collaborations with:
While advancing its internal clinical pipeline, Ascendis Pharma continues to explore partnering opportunities with a range of biopharmaceutical companies.
Our TransCon technology platform creates novel, long-acting prodrugs of proteins, peptides and small molecules with key benefits. Learn More